Bisdemethoxycurcumin

Bisdemethoxycurcumin at a Glance

Bisdemethoxycurcumin (BDMC) is the third and least abundant of turmeric’s three curcuminoids, the curcumin relatives that give the rhizome its orange pigment. Structurally it is curcumin with both methoxy groups removed — where curcumin carries two methoxy substituents on its aromatic rings and demethoxycurcumin carries one, BDMC carries none, leaving two simple para-hydroxyphenyl rings ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}.

That small structural difference has an outsized effect. Losing the methoxy groups makes BDMC the most chemically stable of the three curcuminoids and changes how it behaves in the body: it is a weaker direct radical scavenger than curcumin, yet in several assays it is the strongest at damping NF-κB-driven inflammation ^{1,4Reference 1Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}. Its most distinctive preclinical claim is immunological — an ability to stimulate immune cells to clear amyloid-beta, the peptide that accumulates in Alzheimer’s disease ^{8,9Reference 8Fiala M et al. · 2007Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcuminView study →Reference 9Zhang L et al. · 2006Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patientsView study →}.

The honest headline is that the evidence base is modest and almost entirely preclinical. BDMC is a minor constituent that is rarely isolated for human trials; nearly everything below is in-vitro or rodent work on the isolated molecule, and the clinical curcuminoid record belongs overwhelmingly to curcumin. Like curcumin, it is poorly absorbed by mouth, and its toxicity is low.

The Most Stable Curcuminoid

The point of a BDMC page is what the missing methoxy groups do — and the story cuts two ways.

Stability. Under acidic, alkaline and oxidative stress, the three curcuminoids degrade in a consistent order: BDMC > DMC > curcumin, with BDMC the most resistant to breakdown ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}. Curcumin’s notorious instability — rapid degradation at neutral-to-alkaline pH — is milder in BDMC, which is one reason it survives longer in physiological media and is sometimes described as the more robust curcuminoid to work with ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}.

Antioxidant strength. The same methoxy groups that curcumin uses to stabilise a scavenged radical are absent in BDMC, so as a direct antioxidant it is the weakest of the three: comparative radical-scavenging assays rank curcumin > demethoxycurcumin > BDMC ^{1Reference 1Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →}. “Most stable” and “strongest antioxidant” are therefore not the same thing — BDMC is chemically durable precisely because it is less reactive.

Anti-inflammatory potency. Counterintuitively, in cellular anti-inflammatory readouts BDMC is frequently the most active curcuminoid at suppressing NF-κB signalling, and its lack of an electron-donating methoxy group appears to route it through different inhibitory chemistry than curcumin ^{1,5,10Reference 1Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →Reference 5Wang Y et al. · 2022Bisdemethoxycurcumin attenuates OVA-induced food allergy by inhibiting the MAPK and NF-κB signaling pathwaysView study →Reference 10Sun X et al. · 2024Bisdemethoxycurcumin, a curcumin derivative, ameliorates adjuvant-induced arthritis by suppressing inflammatory reactions and macrophage migrationView study →}. This split — durable and NF-κB-potent, but a weaker radical scavenger — is the compound-unique fingerprint of BDMC and the reason it is studied separately rather than lumped in with curcumin.

What It's Used For

BDMC’s pharmacology overlaps curcumin’s — anti-inflammatory, antioxidant, immunomodulatory and antiproliferative — but the load-bearing caveat is stark: almost all of it is in-vitro or rodent work on the isolated molecule, with no controlled human efficacy trials of BDMC itself.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is preclinical isolate work, so scores stay modest by design.

01Anti-Inflammatory / ImmunomodulatoryShaky42%Multiple rodent models (arthritis, allergy, colitis, cartilage); MAPK/NF-κB suppression ^{5,6,7,10Reference 5Wang Y et al. · 2022Bisdemethoxycurcumin attenuates OVA-induced food allergy by inhibiting the MAPK and NF-κB signaling pathwaysView study →Reference 6Wang Y et al. · 2022AnimalInhibitory effect of bisdemethoxycurcumin on DNCB-induced atopic dermatitis in miceView study →Reference 7Jin G et al. · 2024Bisdemethoxycurcumin, a curcumin, protects chondrocytes and reduces cartilage inflammation via the NRF2/HO-1/NLRP3 pathwayView study →Reference 10Sun X et al. · 2024Bisdemethoxycurcumin, a curcumin derivative, ameliorates adjuvant-induced arthritis by suppressing inflammatory reactions and macrophage migrationView study →}

02Innate Immunity / Anti-AmyloidShaky38%Ex-vivo AD-patient macrophages + mechanism (MGAT-III/TLR, 100 nM optimum) ^{8,9Reference 8Fiala M et al. · 2007Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcuminView study →Reference 9Zhang L et al. · 2006Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patientsView study →}

03AntioxidantShaky30%Comparative radical-scavenging assays; weakest of the three curcuminoids ^{1Reference 1Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →}

04Anticancer / AntiproliferativeShaky28%In-vitro cancer cell lines (ovarian, NSCLC); NF-κB/MMP, autophagy/apoptosis ^{2,3Reference 2Pei H et al. · 2016Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressionsView study →Reference 3Xiang M et al. · 2020Bisdemethoxycurcumin enhances the sensitivity of non-small cell lung cancer cells to icotinib via dual induction of autophagy and apoptosisView study →}

Mechanisms

The load-bearing contrast: removing curcumin’s methoxy groups makes BDMC a poorer direct antioxidant but a potent, differently-routed NF-κB inhibitor, and buys chemical stability ^{1,4Reference 1Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}. The anti-amyloid effect is an innate-immune (phagocytic) action, not a direct anti-plaque one ^{8Reference 8Fiala M et al. · 2007Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcuminView study →}.

Pharmacokinetics

BDMC’s human pharmacokinetics are poorly characterised in isolation, and what is known tracks the curcuminoid family: poor oral absorption, extensive first-pass conjugation and rapid elimination limit systemic exposure ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}. The two BDMC-specific nuances worth stating: (1) BDMC is more chemically stable than curcumin, so it degrades less in solution and physiological media ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}; and (2) in some human formulation studies it appears among the higher-plasma curcuminoids relative to its small dietary share, but these are formulation-dependent and do not establish a reliable bioavailability figure for the isolate. No dependable human Cmax, half-life or absolute oral bioavailability exists for pure BDMC, and its poor absorption is the chief obstacle to translating the preclinical work.

Clinical Trials

There are no controlled efficacy trials of isolated bisdemethoxycurcumin. Human curcuminoid trials use total-curcuminoid or curcumin-standardised extracts, within which BDMC is a minor component; the AD immune work used patient-derived cells ex vivo, not a clinical trial ^{8,9Reference 8Fiala M et al. · 2007Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcuminView study →Reference 9Zhang L et al. · 2006Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patientsView study →}.

Last checked: July 2026.

Isolate vs. Whole-Curcuminoid Studies

The isolate-vs-plant line here is really an isolate-vs-mixture line. The mechanistic and animal work is genuinely on isolated BDMC — the arthritis, food-allergy, atopic-dermatitis, colitis and cancer-cell studies all test the pure compound ^{2,3,5,6,10Reference 2Pei H et al. · 2016Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressionsView study →Reference 3Xiang M et al. · 2020Bisdemethoxycurcumin enhances the sensitivity of non-small cell lung cancer cells to icotinib via dual induction of autophagy and apoptosisView study →Reference 5Wang Y et al. · 2022Bisdemethoxycurcumin attenuates OVA-induced food allergy by inhibiting the MAPK and NF-κB signaling pathwaysView study →Reference 6Wang Y et al. · 2022AnimalInhibitory effect of bisdemethoxycurcumin on DNCB-induced atopic dermatitis in miceView study →Reference 10Sun X et al. · 2024Bisdemethoxycurcumin, a curcumin derivative, ameliorates adjuvant-induced arthritis by suppressing inflammatory reactions and macrophage migrationView study →}, and the comparative antioxidant/stability rankings deliberately separate BDMC from its siblings ^{1,4Reference 1Somparn P et al. · 2007Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivativesView study →Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}. That is a real strength for attribution: where a study says BDMC, it means BDMC.

The human side, by contrast, is always the mixture. Clinical curcuminoid trials dose ~95% total-curcuminoid or curcumin-standardised extracts and rarely quantify BDMC’s individual contribution, so BDMC’s own human efficacy is essentially unstudied. The correct framing: strong isolate preclinical mechanism, no isolate human data, and a clinical record that belongs to the curcuminoid mixture and to curcumin in particular.

Prevalence in Nature

BDMC is essentially confined to Curcuma species, principally the rhizome of turmeric (Curcuma longa), where it occurs as the minor third curcuminoid. Of turmeric’s curcuminoid fraction — itself about 2–9% of the dried rhizome — curcumin makes up roughly 70–77%, demethoxycurcumin about 17%, and BDMC only about 3–8% ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}. It is also reported from related species such as Java turmeric (Curcuma zanthorrhiza) and wild turmeric (Curcuma aromatica). Exact proportions vary widely with cultivar, provenance, season and extraction method, and standardised supplement extracts concentrate the whole curcuminoid fraction (to ~95%) rather than BDMC alone. Because it co-occurs with the other curcuminoids, BDMC is rarely encountered — or consumed — on its own.

Discovery & Synthesis

BDMC was characterised as the third curcuminoid of turmeric, isolated from the curcuminoid fraction once analytical separation distinguished it from curcumin and demethoxycurcumin by the number of methoxy groups on the aromatic rings ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}. Its defining structural feature — two unsubstituted para-hydroxyphenyl rings — makes it the symmetric, fully demethoxylated member of the series.

Manufacture today is chiefly by isolation from turmeric curcuminoid extracts (chromatographic separation of the three curcuminoids) and by total synthesis via the same aldol-type condensation route used for curcumin — an acetylacetone-derived central unit condensed with two equivalents of 4-hydroxybenzaldehyde (rather than vanillin, which supplies curcumin’s methoxy groups). Synthetic BDMC and BDMC-based analogues are of interest partly because the molecule is more chemically stable than curcumin ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}.

Patents: not yet researched.

Toxicity & Safety

BDMC carries a low toxicity flag. It is a natural minor constituent of turmeric — a food with a long dietary history — and shares curcumin’s generally benign safety profile; no isolate-specific toxicity signal of concern has been reported in the preclinical literature.

Safety at a Glance

✅ Low / no toxicity

• Low-toxicity dietary curcuminoid. A minor natural component of turmeric with a long food history and no isolate-specific toxicity signal reported ^{4Reference 4Peram MR et al. · 2017Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditionsView study →}.
• Human safety data are for the mixture, not the isolate. BDMC has not been through dedicated human safety trials on its own; what is known is inferred from whole-curcuminoid extracts and from curcumin.
• Curcuminoid-class cautions carry over. High-dose curcuminoid extracts can cause GI upset and may interact with drug-metabolising enzymes; poor oral absorption limits systemic exposure but also undercuts the preclinical effects.
• Preclinical only. Efficacy figures come from cell and rodent studies at concentrations not achievable from diet or ordinary supplements.

Pregnancy/lactation is a per-herb / per-supplement decision and is not adjudicated on this molecule page; dedicated human reproductive data for isolated BDMC are lacking, and no isolate-specific verdict is issued here.

Dosage

There is no established or recommended human dose for isolated bisdemethoxycurcumin. In practice BDMC is consumed only as the smallest share of turmeric’s curcuminoid fraction — in culinary turmeric and in standardised curcuminoid extracts (typically ~95% total curcuminoids, dominated by curcumin). Cited research figures are preclinical cell and rodent doses that do not convert to human self-dosing, and — as with curcumin — the free compound is poorly absorbed orally, so ingested amounts substantially overstate systemic exposure. Co-administration with piperine raises curcuminoid absorption in general, and hydrogenated relatives such as tetrahydrocurcumin are pursued for better stability and antioxidant behaviour. These are research doses, not a personal recommendation.

References

1. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. (2007). Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biological & Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/17202663/
2. Pei H, Yang Y, Cui L, et al. (2016). Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressions. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/27349797/
3. Xiang M, Jiang HG, Shu Y, et al. (2020). Bisdemethoxycurcumin enhances the sensitivity of non-small cell lung cancer cells to icotinib via dual induction of autophagy and apoptosis. International Journal of Biological Sciences. https://pubmed.ncbi.nlm.nih.gov/32226300/
4. Peram MR, Jalalpure SS, Palkar MB, Diwan PV (2017). Stability studies of pure and mixture form of curcuminoids by reverse phase-HPLC method under various experimental stress conditions. Food Science and Biotechnology. https://pubmed.ncbi.nlm.nih.gov/30263583/
5. Wang Y, Zhang P, Zhang J, et al. (2022). Bisdemethoxycurcumin attenuates OVA-induced food allergy by inhibiting the MAPK and NF-κB signaling pathways. Experimental and Therapeutic Medicine. https://pubmed.ncbi.nlm.nih.gov/35619631/
6. Wang Y, Zhang P, Zhang J, Hong T. (2022). Inhibitory effect of bisdemethoxycurcumin on DNCB-induced atopic dermatitis in mice. Molecules. https://pubmed.ncbi.nlm.nih.gov/36615486/
7. Jin G, et al. (2024). Bisdemethoxycurcumin, a curcumin, protects chondrocytes and reduces cartilage inflammation via the NRF2/HO-1/NLRP3 pathway. Immunity, Inflammation and Disease. https://pubmed.ncbi.nlm.nih.gov/38411358/
8. Fiala M, Liu PT, Espinosa-Jeffrey A, et al. (2007). Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcumin. Proceedings of the National Academy of Sciences USA. https://pubmed.ncbi.nlm.nih.gov/17652175/
9. Zhang L, Fiala M, Cashman J, et al. (2006). Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patients. Journal of Alzheimer’s Disease. https://pubmed.ncbi.nlm.nih.gov/16988474/
10. Sun X, Liang Y, Wang Y, Sun C, Wang X. (2024). Bisdemethoxycurcumin, a curcumin derivative, ameliorates adjuvant-induced arthritis by suppressing inflammatory reactions and macrophage migration. Chemico-Biological Interactions. https://pubmed.ncbi.nlm.nih.gov/38056805/
11. Hsu KY, Ho CT, Pan MH. (2025). Bisdemethoxycurcumin and curcumin alleviate inflammatory bowel disease by maintaining intestinal epithelial integrity and regulating gut microbiota in mice. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/39873626/

View all 11 references▾